(Q38080334)

28 August 2017

Adverse events following yellow fever preventive vaccination campaigns in eight African countries from 2007 to 2010. (English)

1 reference

28 August 2017

0 references

1 reference

J G Breugelmans

1

1 reference

28 August 2017

R F Lewis

2

1 reference

28 August 2017

E Agbenu

3

1 reference

28 August 2017

O Veit

4

1 reference

28 August 2017

D Jackson

5

1 reference

28 August 2017

C Domingo

6

1 reference

28 August 2017

M Böthe

7

1 reference

28 August 2017

W Perea

8

1 reference

28 August 2017

M Niedrig

9

1 reference

28 August 2017

B D Gessner

10

1 reference

28 August 2017

S Yactayo

11

1 reference

28 August 2017

YF AEFI group

12

1 reference

28 August 2017

language of work or name

English

0 references

publication date

7 February 2013

1 reference

28 August 2017

1 reference

28 August 2017

31

1 reference

28 August 2017

14

1 reference

28 August 2017

1819-1829

1 reference

Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases.

28 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.054

Hepatitis and death following vaccination with 17D-204 yellow fever vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.054

Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.054

Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.054

Yellow fever vaccine-associated viscerotropic disease and death in Spain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.054

Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.054

Safety of 17D derived yellow fever vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.054

Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.054

Adverse event reports following yellow fever vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.054

Yellow Fever Vaccine Post-marketing Surveillance in Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.054

Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.054

Aseptic meningitis: case definition and guidelines for collection, analysis and presentation of immunization safety data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.054

Encephalitis, myelitis, and acute disseminated encephalomyelitis (ADEM): case definitions and guidelines for collection, analysis, and presentation of immunization safety data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.054

Viscerotropic disease: case definition and guidelines for collection, analysis, and presentation of immunization safety data

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.054

Advanced Yellow Fever Virus Genome Detection in Point-of-Care Facilities and Reference Laboratories

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.054

Detection of yellow fever virus: a comparison of quantitative real-time PCR and plaque assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.054

Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.054

Assessment of IgG antibodies against yellow fever virus after vaccination with 17D by different assays: neutralization test, haemagglutination inhibition test, immunofluorescence assay and ELISA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.054

Evaluation of an Indirect Immunofluorescence Assay for Detection of Immunoglobulin M (IgM) and IgG Antibodies against Yellow Fever Virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.054

Immune response during adverse events after 17D-derived yellow fever vaccination in Europe

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.054

Comparison of Flavivirus Universal Primer Pairs and Development of a Rapid, Highly Sensitive Heminested Reverse Transcription-PCR Assay for Detection of Flaviviruses Targeted to a Conserved Region of the NS5 Gene Sequences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.054

Detection of enteroviral RNA and specific DNA of herpesviruses by multiplex genome amplification.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.054

Detection of all species of the genus Alphavirus by reverse transcription-PCR with diagnostic sensitivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.054

Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.054

Short report: Incidence of yellow fever vaccine-associated neurotropic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.054

Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan, Ivory Coast

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.054

Neutralizing antibody responses in the major immunoglobulin classes to yellow fever 17D vaccination of humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.054

Interactions between worm infections and malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.054

Early diagnosis of Lassa fever by reverse transcription-PCR.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.054

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2013.01.054

1 reference

release_xxpbcupzkvf5dm64u2kgicmo3m

28 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/xxpbcupzkvf5dm64u2kgicmo3m

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference